Riesgo de heteroirradiación                                                       Risk of heteroirradiation 

Markelewicz RJ Jr, Lorenzen WA, Shusterman S, Grant FD, Fahey FH, Treves ST. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy. Clin Nucl Med. 2013; 38(8):604-7. doi: 10.1097/RLU.0b013e31829af3c8.

Kono Y, Miyamoto Y, Oohashi S, Fukushi M. Radiation exposure to general public after permanent brachytherapy for prostate cancer. Radiat Prot Dosimetry. 2011 146(1-3):229-30.

Castiglia F, Giardina M, Tomarchio E. Risk analysis using fuzzy set theory of  the accidental exposure of medical staff during brachytherapy procedures. J Radiol Prot. 2010 30(1):49-62.

So WK, Chui YY. Women's experience of internal radiation treatment for uterine cervical cancer. J Adv Nurs. 2007 60(2):154-61.

Cattani F, Vavassori A, Polo A, Rondi E, Cambria R, Orecchia R, Tosi G. Radiation exposure after permanent prostate brachytherapy. Radiother Oncol. 2006 79(1):65-9.

Kirisits C, Hefner A, Wexberg P, Pokrajac B, Glogar D, Pötter R, Georg D. Estimation of doses to personnel and patients during endovascular brachytherapy applications. Radiat Prot Dosimetry. 2004;108(3):237-45.

Clapis MJ, Mamede MV. Experiences of women in cesium brachytherapy. Rev Lat Am Enfermagem. 1996; 4(2):131-46.

Versión para imprimir Versión para imprimir | Mapa del sitio
© NAAXPOT SLU © ATIC